Prognostic value of p53 gene mutations in a large series of node- negative breast cancer patients

Cancer Research

Volumn 58, Issue 7, 1998, Pages 1451-1455

  Falette, Nicole ^a   Paperin, Marie Pierre ^a   Treilleux, Isabelle ^a   Gratadour, Anne Christelle ^a   Peloux, Nadine ^a   Mignotte, Hervé ^a   Tooke, Nigel ^b   Löfman, Esfir ^b   Inganäs, Mats ^b   Bremond, Alain ^a   Ozturk, Mehmet ^c   Puisieux, Alain ^a  

^a CENTRE LÉON BÉRARD   (France)

^b GE Healthcare Bio Sciences AB   (Sweden)

^c BILKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; DIAGNOSTIC VALUE; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MIDDLE AGED; MUTATION; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032054823     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bonadonna, G. Conceptual and practical advances in the management of breast cancer. J. Clin. Oncol., 7: 1380-1397, 1989.
2. Early Breast Cancer Trialist's Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet, 339: 1-15, 1992.
3. Fisher, B., Dignam, J., Mamounas, E. P., Costantino, J. P., Wickerham, D. L., Redmond, C., Wolmark N., Dimitrov, N. V., Bowman, D. M., Glass, A. G., Atkins, J. N., Abramson, N., Sutherland, C. M., Aron, B. S., and Margolese, R. G. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen-receptor-negative tumors: eight-year results from National Surgical adjuvant breast and bowel project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J. Clin. Oncol., 14: 1982-1992, 1996.
4. Bieche, I., and Lidereau, R. Genetic alterations in breast cancer. Genes Chromosomes Cancer, 14: 227-251, 1995.
5. Lane, D. P. p53, guardian of the genome. Nature (Lond.), 358: 15-16, 1992.
6. Gottlieb, T. M., and Oren, M. p53 in growth control and neoplasia. Biochim. Biophys. Acta., 1287: 77-102, 1996.
7. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
8. Varley, J. M., Brammar, W. J., Lane, D. P., Swallow, J. E., Dolan, C., and Walker, R. A. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene, 6: 413-421, 1991.
9. Isola, J., Visakorpi, T., Holli, K., and Kallioniemi, O. P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl. Cancer. Inst., 84: 1109-1114, 1992.
10. Thor, A. D., Moore, II, D. H., Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwanz, L., Chen, L. C., Mayall, B. H., and Smith, H. S. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst., 84: 845-855, 1992.
11. Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A., Brown, R. W., Chamness, G. C., Osborne, C. K., and McGuire, W. L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome of node-negative breast cancer. J. Natl. Cancer. Inst., 85: 200-206, 1993.
12. Thor, A. D., and Yandell DW. Prognostic significance of p53 overexpression in node-negative breast carcinoma preliminary studies support cautious optimism. J. Natl. Cancer. Inst., 85: 176-177, 1993.
13. Poller, D. N., Hutchings, C. E., Galea, M., Bell, J. A., Nicholson, R. A., Elston, C. W., Blamey, R. W., and Ellis, I. O. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and estrogen receptor. Br. J. Cancer, 66: 583-588, 1992.
14. Silvestrini, R., Benini, E., Grazia Daidone, M., Veneroni, S., Boracchi, P., Cappelletti, V., Di Fronzo, G., and Veronesi, U. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 85: 965-970, 1993.
15. Barnes, D. M., Dublin, E. A., Fisher, C. J., Levison, D. A., and Millis, R. R. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum. Pathol., 24: 469-476, 1993.
16. Elledge, R. M., Clark, G. M., Fuqua, S. A., Yu, Y. Y., and Allred, D. C. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res., 54: 3752-3757, 1994.
17. Bergh, J., Norberg, T., Sjögren, S., Lindgren, A., and Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med., 1: 1029-1034, 1995.
18. Kovach, J. S., Hartmann, A., Blaszyk, H., Cunningham, J., Schaid, D., and Sommer, S. S. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc. Natl. Acad. Sci. USA, 93: 1093-1096, 1996.
19. Elston, C. W., and Ellis, I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19: 403-410, 1991.
20. Sjögren, S., Inganäs, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L., and Bergh, J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst., 88: 173-182, 1996.
21. Moll, U. M., Riou, G., and Levine, A. J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA, 89: 7262-7266, 1992.
22. Cattoretti, G., Rilke, F., Andreola, S., D'Amato, L., and Delia, D. p53 expression in breast cancer. Int. J. Cancer, 41: 178-183, 1988.
23. Andersen, T. I., Holm, R., Nesland, J. M., Heimdal, K. R., Ottestad, L., and Börresen, A. L. Prognostic significance of TP53 alterations in breast carcinoma. Br. J. Cancer, 68: 540-548, 1993.
24. Jacquemier, J., Molès, J. P., Penault-Llorca, F., Adelaide, J., Torrente, M., Viens, P., Birnbaum, D., and Theillet, C. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br. J. Cancer, 69: 846-852, 1994.
25. Silvestrini, R., Veneroni, S., Benini, E., Daidone, M. G., Luisi, A., Leutner, M., Maucione A., Kenda, R., Zucali, R., and Veronesi, U. Expression of p53, glutathione S-transferase-π, and Bcl2 proteins and benefit from adjuvant radiotherapy in breast cancer J. Natl. Cancer Inst., 89: 639-645, 1997.
26. Thorlacius, S., Thorgilsson, B., Björnsson, J., Tryggvadottir, L., Börresen, A. L., Ogmundsdottir, H. M., and Eyfjörd, J. E. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur. J. Cancer, 31A: 1856-1861, 1995.
27. Blaszyk, H., Hartmann, A., Tamura, Y., Saitoh, J. M., Cunningham, J. M., McGovern. R. M., Schroeder, J. J., Schaid, D. J., Li, K., Monden, Y., Morimoto, T., Komaki, K., Sasa, M., Hirata, K., Okazaki, M., Kovach, J. S., and Sommer, S. S. Molecular epidemiology of breast cancers in northern and southern Japan: the frequency, clustering and patterns of p53 gene mutations differ among these two low-risk populations. Oncogene, 13: 2159-2166, 1996.
28. Elledge, R. M., Fuqua, S. A., Clark, G. M., Pujol, P., Allred, D. C., McGuire, W. L. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res. Treat., 26: 225-235, 1993.
29. Seshadri, R., Leong, A. S., McCaul, K., Figaira, F. A., Setlur, V., and Horsfall, D. J. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int. J. Cancer. 69: 135-141, 1996.
30. Caleffi, M., Teague, M. W., Jensen, R. A., Vnencak-Jones, C. L., Dupont, W. D., and Parl, F. F. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer (Phila.), 73: 2147-2156, 1994.
31. Sommer, S. S., Cunningham, J., McGovern, R. M., Saitoh, S., Schroeder, J. J., Wold, L. E., and Kovach, J. S. Pattern of p53 gene mutations in breast cancers of women of the midwestern United States. J. Natl. Cancer Inst., 84: 246-252, 1992.
32. Jansson, T., Inganäs, M., Sjogren, S., Norberg, T., Lindgren, A., Holmberg, L., and Bergh, J. p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J. Clin. Oncol., 13: 2745-2751, 1995.
33. Guillot, C., Falette, N., Courtois, S., Voeltzel, T., Garcia, E., Ozturk, M., and Puisieux, A. Alteration of p53 damage response by tamoxifen treatment. Clin. Cancer Res., 2: 1439-1444, 1996.
34. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
35. Lowe, S. W., Bodis, S., McClatchey, A. M., Remington, L., Ruley, H. E., Fischer, D. A., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
36. Fan, S., Smith, M. L., Rivet, D. J., II, Duba, D., Zhan, Q., Kohn, K. W., Fornace, A. J., Jr., and O'Connor, P. M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55: 1649-1654, 1995.
37. Hawkins, D. S., Demers, G. W., and Galloway, D. A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56: 892-898, 1996.